Skip to main content

ASTRO 2015

ecancer.org

Highlights and interviews from the 2015 ASTRO conference



rss RSS

10
RESULTS


Show sorted alphabetically

Show sorted alphabetically

SHOW DETAILS
up-solid down-solid
eye
Title
Date Published
Creator
ASTRO 2015
Nov 12, 2015 Dr David Palma – London Health Sciences Centre, London, Canada
movies

eye 3

favorite 0

comment 0

Dr Palma talks to ecancertv at ASTRO 2015 about the concept of oligometastases and how novel approaches such as stereotactic radiation therapy may be used to treat patients with multiple metastases. In the interview he notes that better evidence is needed to determine which patients may benefit from such an approach and comments on research being conducted by the London Health Sciences Centre in collaboration with the VUmc Cancer Center in Amsterdam.
ASTRO 2015
Nov 12, 2015 Dr Morten Høyer - Aarhus University Hospital, Aarhus, Denmark
movies

eye 6

favorite 0

comment 0

Dr Hoyer talks to ecancertv at ASTRO 2015 about his lecture during the ASTRO/ESTRO Joint Session 'Novel treatment approaches for oligometastases'. In the interview he provides background on how oligometastases have been managed in the past and how stereotactic body radiation therapy (SBRT) is being used to enable the precise targetting of these lesions. Specifically, Dr Hoyer talks about the survival of patients who receive SBRT for oligometastases of colorectal cancer.
ASTRO 2015
Nov 12, 2015 Ron DiGiaimo – Revenue Cycle Inc, Austin, USA
movies

eye 2

favorite 0

comment 0

Mr DiGiaimo talks to ecancertv at ASTRO 2015 about some of his research highlights and the potential economic considerations of using newer radiation technologies over conventional standards.
ASTRO 2015
Nov 12, 2015 Dr Mohamed Abazeed – Cleveland Clinic, Cleveland, USA
movies

eye 6

favorite 0

comment 0

Dr Abazeed talks to ecancertv at ASTRO 2015 about research being conducted at the Cleveland Clinic looking at whether it is possible to use genomic parameters to predict how tumours will respond to radiation therapy. In the interview he highlights that there is an underlying genetic diversity of cancer itself and a heterogeneous genetic response to radiation.
ASTRO 2015
Nov 12, 2015 Dr Brian Kavanagh - University of Colorado Cancer Centre, Aurora, USA
movies

eye 2

favorite 0

comment 0

Dr Kavanagh, President-elect to the ASTRO board of directors, talks to ecancertv about the theme of ASTRO 2015 – Technology Meets Patient Care – and how the research and presentations being given relate to this. In the interview he highlights research that is not only comparing the effectiveness of the different types of radiotherapy but also focussing on reducing the toxicity associated with radiation treatment. Initiatives to improve patient care are not just about using the best...
ASTRO 2015
Nov 12, 2015 Dr Bruce Haffty - Rutgers Cancer Institute of New Jersey, New Brunswick, USA
movies

eye 4

favorite 0

comment 0

Dr Haffty talks to ecancertv at ASTRO 2015 about some of the research highlights of the meeting including the Presidential Symposium, which looks at the role of radiation therapy in the multidisciplinary management of gastrointestinal malignancies. In the interview he also outlines some of the recent research that he has been involved with and talks about the use of radiation oncology in treating breast cancer. In addition, Dr Haffty discusses some of the initiatives and programmes that ASTRO...
ASTRO 2015
Nov 12, 2015 Dr Joe Chang – University of Texas MD Anderson Cancer Center, Houston, USA
movies

eye 2

favorite 0

comment 0

Dr Chang talks to ecancertv at ASTRO 2015 about the use of stereotactic body radiation therapy (SBRT) in non-small cell lung cancer (NSCLC) and whether it can be used in patients with early disease that is still operable. He explains that SBRT is being used in early NSLC but that this is usually in inoperable cases and it could be an option in some patients with operable stage I tumours. Future directions would include look at using SBRT with immunotherapy.
ASTRO 2015
Nov 12, 2015 Dr Theodore Hong - Massachusetts General Hospital, Boston, USA
movies

eye 2

favorite 0

comment 0

Dr Hong talks to ecancertv at ASTRO 2015 about a prospective, open-label phase II, study of proton-based stereotactic body radiotherapy (SBRT) in patients with liver metastases. The study findings showed that proton SBRT was associated with high rates of local control and that there was a favourable toxicity profile. No patient developed grade 3 or higher radiotherapy-related toxicity.
ASTRO 2015
Nov 12, 2015 Dr David Palma – London Health Sciences Centre, London, Canada
movies

eye 2

favorite 0

comment 0

Dr Palma talks to ecancertv at ASTRO 2015 about a session on using stereotactic radiation therapy for early-stage nonsmall-cell lung cancer (NSCLC). During the session talks were given on using the method for operable stage 1 NSCLC and on the risk for recurrence following stereotactic radiation therapy. Speakers also looked at aggressive local therapy for oligometastases and the potential for using stereotactic radiation therapy in combination with immunotherapy. Dr Palma also comments on the...
ASTRO 2015
Nov 12, 2015 Dr Theodore Hong - Massachusetts General Hospital, Boston, USA
movies

eye 5

favorite 0

comment 0

Dr Hong talks to ecancertv about one of the nursing sessions held at ASTRO 2015 that looked at the care of patients receiving chemoradiation. In the interview he outlines that the aims of the session were to provide an overview of the data and rationale for why certain chemoradiation strategies were developed and explain why chemotherapy and radiotherapy may be used concurrently or sequentially. Another focus was to look at toxicity and the management of side effects commonly seen with...